Ombow, Samyang would have to run many clinical trials in Asia, in a similar process to what happens for US and European regulatory approval.
But if Samyang can run their own trials using Cortex's two lead compounds, unfortunately that would greatly diminish Cortex's ability to partner those 2 compounds to other Pharmas for other territories and indications. Perhaps Neuro will chime in on the topic if he's out there.
Market Data 
Markets 
AI
